356 related articles for article (PubMed ID: 32677994)
1. Role of CD47 in Hematological Malignancies.
Eladl E; Tremblay-LeMay R; Rastgoo N; Musani R; Chen W; Liu A; Chang H
J Hematol Oncol; 2020 Jul; 13(1):96. PubMed ID: 32677994
[TBL] [Abstract][Full Text] [Related]
2. Blocking "don't eat me" signal of CD47-SIRPα in hematological malignancies, an in-depth review.
Russ A; Hua AB; Montfort WR; Rahman B; Riaz IB; Khalid MU; Carew JS; Nawrocki ST; Persky D; Anwer F
Blood Rev; 2018 Nov; 32(6):480-489. PubMed ID: 29709247
[TBL] [Abstract][Full Text] [Related]
3. An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity.
Wang X; Wang Y; Hu J; Xu H
Cancer Med; 2021 Mar; 10(6):2125-2136. PubMed ID: 33629544
[TBL] [Abstract][Full Text] [Related]
4. Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody.
Narla RK; Modi H; Bauer D; Abbasian M; Leisten J; Piccotti JR; Kopytek S; Eckelman BP; Deveraux Q; Timmer J; Zhu D; Wong L; Escoubet L; Raymon HK; Hariharan K
Cancer Immunol Immunother; 2022 Feb; 71(2):473-489. PubMed ID: 34247273
[TBL] [Abstract][Full Text] [Related]
5. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
[TBL] [Abstract][Full Text] [Related]
6. Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis.
Zhang W; Huang Q; Xiao W; Zhao Y; Pi J; Xu H; Zhao H; Xu J; Evans CE; Jin H
Front Immunol; 2020; 11():18. PubMed ID: 32082311
[TBL] [Abstract][Full Text] [Related]
7. Progress of CD47 immune checkpoint blockade agents in anticancer therapy: a hematotoxic perspective.
Chen YC; Shi W; Shi JJ; Lu JJ
J Cancer Res Clin Oncol; 2022 Jan; 148(1):1-14. PubMed ID: 34609596
[TBL] [Abstract][Full Text] [Related]
8. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.
Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC
J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251
[TBL] [Abstract][Full Text] [Related]
9. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding.
Puro RJ; Bouchlaka MN; Hiebsch RR; Capoccia BJ; Donio MJ; Manning PT; Frazier WA; Karr RW; Pereira DS
Mol Cancer Ther; 2020 Mar; 19(3):835-846. PubMed ID: 31879362
[TBL] [Abstract][Full Text] [Related]
10. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
[TBL] [Abstract][Full Text] [Related]
11. A single-valent long-acting human CD47 antagonist enhances antibody directed phagocytic activities.
Wu F; Qiu Y; Xu Y
Cancer Immunol Immunother; 2020 Dec; 69(12):2561-2569. PubMed ID: 32583154
[TBL] [Abstract][Full Text] [Related]
12. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
13. Cancer immunotherapy targeting the CD47/SIRPα axis.
Weiskopf K
Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
[TBL] [Abstract][Full Text] [Related]
14. The regulation of CD47-SIRPα signaling axis by microRNAs in combination with conventional cytotoxic drugs together with the help of nano-delivery: a choice for therapy?
Beizavi Z; Gheibihayat SM; Moghadasian H; Zare H; Yeganeh BS; Askari H; Vakili S; Tajbakhsh A; Savardashtaki A
Mol Biol Rep; 2021 Jul; 48(7):5707-5722. PubMed ID: 34275112
[TBL] [Abstract][Full Text] [Related]
15. [Role of CD47 in hematologic malignancies].
Su GH; Zhao YL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1631-4. PubMed ID: 24370062
[TBL] [Abstract][Full Text] [Related]
16. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
Voets E; Paradé M; Lutje Hulsik D; Spijkers S; Janssen W; Rens J; Reinieren-Beeren I; van den Tillaart G; van Duijnhoven S; Driessen L; Habraken M; van Zandvoort P; Kreijtz J; Vink P; van Elsas A; van Eenennaam H
J Immunother Cancer; 2019 Dec; 7(1):340. PubMed ID: 31801627
[TBL] [Abstract][Full Text] [Related]
17. CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises.
Tong B; Wang M
Future Oncol; 2018 Sep; 14(21):2179-2188. PubMed ID: 29667847
[TBL] [Abstract][Full Text] [Related]
18. Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy.
Zhang J; Jin S; Guo X; Qian W
J Int Med Res; 2018 Nov; 46(11):4418-4426. PubMed ID: 30226089
[TBL] [Abstract][Full Text] [Related]
19. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.
Treffers LW; Ten Broeke T; Rösner T; Jansen JHM; van Houdt M; Kahle S; Schornagel K; Verkuijlen PJJH; Prins JM; Franke K; Kuijpers TW; van den Berg TK; Valerius T; Leusen JHW; Matlung HL
Cancer Immunol Res; 2020 Jan; 8(1):120-130. PubMed ID: 31690649
[TBL] [Abstract][Full Text] [Related]
20. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.
Upton R; Banuelos A; Feng D; Biswas T; Kao K; McKenna K; Willingham S; Ho PY; Rosental B; Tal MC; Raveh T; Volkmer JP; Pegram MD; Weissman IL
Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34257155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
